Torrent Pharmaceuticals Limited
All news and filings related to Torrent Pharmaceuticals Limited.
View all news & filings- Medium impact
Torrent Pharma Shareholders Approve Shanti Ekambaram as Independent Director
Torrent Pharmaceuticals Limited shareholders approved the appointment of Shanti Ekambaram as an Independent Director via postal ballot. The e-voting concluded on September 6, 2026. The resolution passed with 99.98% of valid votes in favour, announced on September 7, 2026.
Read the summary - Low impact
Torrent Pharma to Participate in Emkay Confluence 2026 Investor Meet on Aug 14
Torrent Pharmaceuticals Limited representatives will attend the Emkay - Confluence 2026 investor meet in Mumbai on August 14, 2026. The event includes group and one-on-one meetings with investors. The schedule may be subject to change.
Read the summary - Low impact
Torrent Pharmaceuticals Assigned ESG Rating of 70 by NSE Sustainability Ratings
Torrent Pharmaceuticals Limited has received an ESG Rating of 70 from NSE Sustainability Ratings and Analytics Limited. This rating was assigned by a SEBI registered ESG Rating Provider.
Read the summary - Low impact
Torrent Pharma Completes Dispatch of Postal Ballot Notice on August 5, 2026
Torrent Pharmaceuticals Limited completed the dispatch of its Postal Ballot Notice on August 5, 2026. The notice was sent electronically to eligible members based on a July 31, 2026, cut-off date. Newspaper publications confirming this were made on August 5, 2026.
Read the summary - Medium impact
Torrent Pharma proposes appointment of Shanti Ekambaram as Independent Director via Postal Ballot
Torrent Pharmaceuticals Limited is seeking shareholder approval for the appointment of Shanti Ekambaram as an Independent Director. The e-voting period runs from August 8, 2026, to September 6, 2026. The result will be announced by September 8, 2026. Ms. Ekambaram has extensive experience in financial services.
Read the summary - Low impact
Torrent Pharma Q1 FY27 Earnings Call Transcript Released
Torrent Pharmaceuticals Limited has published the transcript for its Q1 FY27 earnings call. The call discussed financial results for the quarter ending June 30, 2026. The transcript is accessible on the company's investor relations website.
Read the summary - Low impact
Torrent Pharma: Ameera Shah Ceases as Independent Director Upon Completion of Term on Aug 1, 2026
Ameera Shah has completed her term as an Independent Director of Torrent Pharmaceuticals Limited, ceasing her role on August 1, 2026. The company has officially notified the stock exchanges about this change.
Read the summary - Low impact
Torrent Pharma Places Audio Recording of Q1 FY27 Investor Call on Website
Torrent Pharmaceuticals has made the audio recording of its investor conference call for the quarter ended June 30, 2026, available on its website. This follows their previous letter dated July 17, 2026.
Read the summary - Medium impact
Torrent Pharma: Hasmukh Patel, Sushil Jaiswal & Sunil Nadkarni Cease as Senior Management
Torrent Pharmaceuticals Limited announced that Hasmukh Patel, Sushil Jaiswal, and Sunil Nadkarni have ceased to be part of the Senior Management. This change is effective from July 30, 2026, and is attributed to a revised reporting structure within the company.
Read the summary - High impact
Torrent Pharma Q1 FY27 Revenue Rises 55% to ₹4,921 Cr, PAT at ₹566 Cr
Torrent Pharmaceuticals reported Q1 FY27 consolidated revenues of ₹4,921 crore, a 55% YoY increase. Net profit after tax was ₹566 crore. India business revenues grew 19% to ₹2,157 crore. US revenues were up 36% to ₹418 crore, and Brazil revenues increased by 27% to ₹277 crore. JB Business revenues grew 10% to ₹1,201 crore.
Read the summary - High impact
Torrent Pharma Q1 FY27 Revenue Surges 55% YoY to ₹4,921 Crore; Net Profit ₹566 Crore
Torrent Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹4,921 crore, up 55% YoY. Net profit after tax was ₹566 crore. The India business revenue grew 19% to ₹2,157 crore. US revenue increased 36% to ₹418 crore. JB Business revenue was up 10% to ₹1,201 crore.
Read the summary - Medium impact
Torrent Pharma Appoints Shanti Ekambaram as Additional Independent Director
Torrent Pharmaceuticals Limited has appointed Shanti Ekambaram as an Additional Independent Director, effective July 30, 2026. She brings 39 years of financial services experience, including a leadership role at Kotak Mahindra Bank. Her appointment is for a three-year term, pending shareholder approval.
Read the summary - Medium impact
Torrent Pharma Receives Final Listing Approval for 4.19 Cr Equity Shares Post JB Chemicals Amalgamation
Torrent Pharmaceuticals Limited has received final listing and trading approval for 4,19,22,416 equity shares. These shares were allotted following the amalgamation of J. B. Chemicals & Pharmaceuticals Limited. The shares will be listed and traded on NSE and BSE effective July 28, 2026.
Read the summary - Medium impact
Torrent Pharma Allots 4.19 Cr Shares in J.B. Chemicals Amalgamation
Torrent Pharmaceuticals allotted 4,19,22,416 equity shares to J.B. Chemicals shareholders on July 20, 2026, as part of their amalgamation scheme. The share exchange ratio is 51 Torrent Pharma shares for every 100 J.B. Chemicals shares. This increases Torrent Pharma's paid-up capital to ₹1,90,18,39,280.
Read the summary - Low impact
Torrent Pharma announces dissolution of its Philippines subsidiary, Curatio Inc.
Torrent Pharmaceuticals Limited announced the voluntary dissolution of its Philippines subsidiary, Curatio Inc., effective July 10, 2026. The subsidiary contributed Nil to turnover and had a net worth of ₹1.3 Crores as of March 31, 2026. The dissolution was completed via an amendment to its articles of incorporation.
Read the summary - Low impact
Torrent Pharma Assigned Strong ESG Ratings by Crisil ESG Ratings
Torrent Pharmaceuticals Limited has been assigned strong ESG ratings by Crisil ESG Ratings & Analytics Limited. The company received a 'Crisil ESG 66' rating and a 'Crisil Core ESG 74' rating.
Read the summary - Low impact
Torrent Pharma Schedules Conference Call for Q1 FY27 Financial Results on July 30th
Torrent Pharmaceuticals will hold a conference call on July 30, 2026, to discuss financial results for the quarter ended June 30, 2026. Dial-in details and registration links are provided.
Read the summary - High impact
Torrent Pharma Completes Amalgamation with JB Chemicals, Scheme Effective July 8
Torrent Pharmaceuticals Limited has completed the amalgamation with J. B. Chemicals & Pharmaceuticals Limited, effective July 8, 2026. The scheme was sanctioned by the NCLT on July 6, 2026. The Appointed Date for the amalgamation is January 21, 2026. The company's capital clause has been amended to reflect the merged entity.
Read the summary - High impact
Torrent Pharma Completes Amalgamation with JB Chemicals; Scheme Effective July 8
Torrent Pharmaceuticals Limited announced its amalgamation with J. B. Chemicals & Pharmaceuticals Limited is effective from July 8, 2026. The scheme was sanctioned by NCLT on July 6, 2026. JB Chemicals is now dissolved and amalgamated with Torrent Pharma. The company's capital has been amended to ₹255.30 crore.
Read the summary - Medium impact
Torrent Pharma Fixes July 17, 2026 as Record Date for J.B. Chemicals Amalgamation
Torrent Pharmaceuticals has set July 17, 2026, as the record date for its amalgamation with J. B. Chemicals & Pharmaceuticals. Shareholders of J.B. Chemicals will receive 51 Torrent Pharma shares for every 100 shares held, as per the sanctioned scheme.
Read the summary - High impact
Torrent Pharma's Amalgamation Scheme with JB Chemicals Sanctioned by NCLT
Torrent Pharmaceuticals Limited's Scheme of Amalgamation with J. B. Chemicals & Pharmaceuticals Limited has been sanctioned by the Hon'ble National Company Law Tribunal (NCLT), Ahmedabad Bench. The order was pronounced on July 6, 2026. The amalgamation will become effective upon filing the certified order copy with the Registrar of Companies.
Read the summary - Low impact
Torrent Pharma Closes Trading Window from July 1, 2026, for Q1FY27 Financial Results
Torrent Pharmaceuticals Limited will close its trading window for designated persons from July 1, 2026. The window will reopen 48 hours after the submission of financial results for the quarter ended June 30, 2026, to the stock exchanges.
Read the summary - Medium impact
Torrent Pharma's 53rd AGM: Shareholders Approve All Resolutions, Including Financials and Dividend
Torrent Pharmaceuticals Limited's 53rd AGM on June 23, 2026, saw shareholders approve all resolutions. This included adopting financial statements for FY26, confirming an interim dividend of ₹29.00, and declaring a final dividend of ₹9.00 per share. The re-appointment of Director Samir Mehta and issuance of equity shares were also approved.
Read the summary - Low impact
Torrent Pharma holds 53rd AGM on June 23, 2026, approves FY26 financials and dividends.
Torrent Pharmaceuticals Limited held its 53rd AGM on June 23, 2026. The company approved standalone and consolidated financial statements for FY26 and declared dividends. An interim dividend of ₹29.00 and a final dividend of ₹9.00 per share were confirmed and declared, respectively. Key business transacted included director appointments and auditor remuneration ratification.
Read the summary - Low impact
Torrent Pharmaceuticals Announces 53rd AGM on June 23, 2026; Annual Report for FY26 Disclosed
Torrent Pharmaceuticals will hold its 53rd Annual General Meeting on June 23, 2026, via Video Conference. The Integrated Annual Report for FY 2025-26 is now available. Shareholders are advised to update their email addresses for future communications.
Read the summary - Low impact
Torrent Pharmaceuticals Publishes Newspaper Advertisement for 53rd AGM and E-Voting
Torrent Pharmaceuticals published newspaper ads for its 53rd AGM and E-Voting procedure on June 2, 2026. The ads appeared in the Financial Express (English and Gujarati). This is a routine notification for shareholders.
Read the summary - Low impact
Torrent Pharma Releases Business Responsibility and Sustainability Report for FY26
Torrent Pharmaceuticals Limited has released its Business Responsibility and Sustainability Report for FY 2025-26. The report, audited by Grant Thornton Bharat LLP, details the company's ESG commitments and performance across climate change, resource management, human capital, and governance. It aligns with NGRBC principles and includes material issue assessments.
Read the summary - Low impact
Torrent Pharma to Participate in BoFA and Citi India Conferences on June 3-4, 2026
Torrent Pharmaceuticals Limited representatives will attend the BoFA - 2026 India Conference on June 3, 2026, and Citi's 2026 India Conference on June 4, 2026, both in Mumbai. These meetings will involve group and one-on-one sessions with investors. The schedule is subject to change.
Read the summary - Low impact
Torrent Pharma Announces 53rd AGM on June 23, 2026, via VC/OAVM
Torrent Pharmaceuticals Limited will hold its 53rd Annual General Meeting on June 23, 2026. The meeting will take place at 09:30 a.m. via Video Conferencing / Other Audio Visual Means (VC / OAVM). This announcement was published on May 28, 2026.
Read the summary - Low impact
Torrent Pharma Uploads Q4FY26 Earnings Call Transcript
Torrent Pharmaceuticals Limited has published the transcript of its conference call concerning the audited financial results for the quarter and year ended March 31, 2026. The transcript is available on the company's website.
Read the summary - Low impact
Torrent Pharma places audio recording of conference call on audited financial results for FY26 on website
Torrent Pharmaceuticals has made the audio recording of its conference call regarding audited financial results for the quarter and year ended March 31, 2026, available on its website. This follows previous communications on May 12 and May 16, 2026.
Read the summary - Low impact
Torrent Pharma Fixes May 29, 2026, as Record Date for Final Dividend
Torrent Pharmaceuticals Limited has set Friday, May 29, 2026, as the record date. This is for determining shareholders eligible for the final dividend for the financial year 2025-26, if declared. The announcement was made as per SEBI Listing Regulations.
Read the summary - High impact
Torrent Pharma Board Approves FY26 Results, Recommends ₹9 Dividend and ₹5,000 Cr QIP.
Torrent Pharmaceuticals approved its FY26 audited financial results. The company recommended a final dividend of ₹9 per share and proposed a QIP of up to ₹5,000 crores. For Q4FY26, revenue was ₹2,735 crore and net profit was ₹467 crore. For FY26, revenue reached ₹10,712 crore with a net profit of ₹2,192 crore.
Read the summary - High impact
Torrent Pharma Approves FY26 Results, Recommends ₹9 Dividend & ₹5,000 Cr QIP.
Torrent Pharmaceuticals Limited reported audited financial results for FY26. The company recommended a final dividend of ₹9 per share and proposed a QIP of up to ₹5,000 crores. Revenue from operations for FY26 was ₹10,712 crores, with a net profit of ₹2,192 crores. The record date for the dividend is May 29, 2026.
Read the summary - High impact
Torrent Pharma Q4 FY26 Revenue Rises 42% to ₹4,197 Crore
Torrent Pharmaceuticals reported Q4 FY26 revenue of ₹4,197 crore, a 42% increase. Full-year FY26 revenue reached ₹13,980 crore, up 21%. Key growth drivers include India (Q4: ₹2,215 crore, +43%) and Brazil (Q4: ₹455 crore, +30%). The company submitted its audited financial results for the quarter and year ended March 31, 2026.
Read the summary - High impact
Torrent Pharma Approves FY26 Results, Recommends ₹9 Dividend, Eyes ₹5,000 Cr QIP
Torrent Pharmaceuticals announced its FY26 results, with total revenue at ₹10,712 crore and net profit at ₹2,192 crore. The company recommended a final dividend of ₹9 per share and plans to seek approval for raising up to ₹5,000 crore via QIP. The record date for the dividend is May 29, 2026.
Read the summary - Low impact
Torrent Pharma Publishes Newspaper Advertisement Regarding Share Transfer to IEPF
Torrent Pharmaceuticals Limited published newspaper advertisements on May 21, 2026, regarding the transfer of shares to the Investor Education and Protection Fund (IEPF). The advertisements were published in the English and Gujarati editions of "Financial Express". The company has informed BSE and NSE about this regulatory filing.
Read the summary - Low impact
Torrent Pharma Reschedules Investor Conference Call to May 22, 2026
Torrent Pharmaceuticals Limited has rescheduled its investor conference call to May 22, 2026, at 5:30 PM IST. The call will discuss the financial performance for the quarter and year ended March 31, 2026. Dial-in details remain unchanged.
Read the summary - Low impact
Torrent Pharma Schedules Post-Quarterly Results Conference Call for March 31, 2026 Quarter
Torrent Pharmaceuticals will host an investor and analyst conference call on May 22, 2026, at 06:30 PM to discuss financial results for the quarter and year ended March 31, 2026. Dial-in details and registration links are provided.
Read the summary - Low impact
Torrent Pharma publishes newspaper notice regarding J.B. Chemicals amalgamation petition hearing.
Torrent Pharmaceuticals Limited has published a notice regarding the hearing of a petition for the amalgamation of J.B. Chemicals & Pharmaceuticals Limited with Torrent Pharma. The notice was published in various newspapers on May 11, 2026.
Read the summary - Low impact
Torrent Pharma Publishes Newspaper Ad for Special Window on Physical Share Transfers
Torrent Pharmaceuticals Limited published newspaper advertisements on May 8th, 2026, in the Financial Express (English and Gujarati). The ads concern a special window for the transfer and dematerialization of physical shares. The company has informed BSE and NSE.
Read the summary - High impact
Torrent Pharma Shareholders Approve Amalgamation with JB Pharma
Torrent Pharmaceuticals Limited shareholders approved the amalgamation with J. B. Chemicals & Pharmaceuticals Limited during a meeting held on April 28, 2026. The scheme received approval by the required majority through both remote e-voting and in-meeting voting.
Read the summary - High impact
Torrent Pharma Shareholders Approve Amalgamation of JB Chemicals
Torrent Pharmaceuticals Limited's equity shareholders approved the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited. The approval was secured during an NCLT-convened meeting on April 28, 2026. Shareholders voted in favor of the amalgamation, with promoters and public shareholders participating.
Read the summary - High impact
Torrent Pharma shareholders approve amalgamation scheme with J.B. Chemicals
Torrent Pharmaceuticals Limited shareholders approved the amalgamation scheme with J.B. Chemicals & Pharmaceuticals Limited on April 28, 2026. The approval was secured with the required majority through e-voting. The company will separately disclose the detailed voting results.
Read the summary - Medium impact
Torrent Pharma's Bileshwarpura facility inspection by USFDA concludes with zero observations.
Torrent Pharmaceuticals Limited's Bileshwarpura (Oncology) facility successfully completed a USFDA inspection. The inspection, held from April 6 to April 10, 2026, concluded with zero observations, indicating a positive outcome for the facility's compliance standards.
Read the summary - Low impact
Torrent Pharma Sells 50,000 Shares of UNM Foundation to Holding Company for ₹5 Lakhs
Torrent Pharmaceuticals sold 50,000 equity shares of UNM Foundation to its holding company, Torrent Investments Limited, for ₹5 lakhs on March 30, 2026. This is a related party transaction conducted on an arm's length basis.
Read the summary - Low impact
Torrent Pharma Announces NCLT Convened Meeting of Equity Shareholders on April 28, 2026
Torrent Pharmaceuticals Limited will hold an NCLT convened meeting for equity shareholders on April 28, 2026. The meeting will be conducted via video conference. This announcement follows an NCLT order dated March 23, 2026.
Read the summary - Low impact
Torrent Pharma Closes Trading Window from April 1, 2026, for FY26 Audited Financial Results
Torrent Pharmaceuticals Limited will close its trading window for designated persons from April 1, 2026. The window will reopen 48 hours after the submission of audited financial results for the fiscal year ending March 31, 2026.
Read the summary - Medium impact
Torrent Pharma to hold shareholders' meeting on April 28, 2026, for J.B. Chemicals amalgamation approval
Torrent Pharmaceuticals Limited will hold a shareholder meeting on April 28, 2026, to approve the amalgamation scheme with J.B. Chemicals & Pharmaceuticals Limited. Remote e-voting is available from April 24 to April 27, 2026. The meeting will be conducted via video conference.
Read the summary - Medium impact
Torrent Pharma to hold Equity Shareholders Meeting on April 28, 2026, for J.B. Chemicals Amalgamation
Torrent Pharmaceuticals Limited will hold an equity shareholders meeting on April 28, 2026, to approve the amalgamation scheme with J. B. Chemicals & Pharmaceuticals Limited. Remote e-voting is open from April 24 to April 27, 2026. Shareholders as of April 21, 2026, are eligible to vote.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio